secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-08-11T20:10:31+00:00
Accession:  0001746473-26-000115
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q2 2026 net loss narrows to $22.4M; FORTIFY enrollment ahead of schedule
--------------------------------------------------------------------------------

- Q2 2026 net loss $22.4M vs $43.3M prior-year; R&D spend $16.7M vs $32.2M, G&A $7.1M vs $13.4M on bexotegrast termination and headcount cuts.
- Cash, equivalents and short-term investments of $159.6M at June 30, 2026; expected to fund operations into second half of 2028.
- FORTIFY Phase 1b trial of PLN-101095 enrolling ahead of schedule; up to 102 patients across 3 cohorts; interim data expected 2027.
- Appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. (Jazz Pharmaceuticals EVP R&D/CMO) to Board of Directors.
- AACR data: PLN-101095 monotherapy raised IFN-γ, CXCL9 and granzyme-B only in responders, signaling T-cell reactivation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/0001746473-26-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000115/plrx-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer